<DOC>
	<DOC>NCT00498407</DOC>
	<brief_summary>Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational Medicinal Products (IMPs), will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks until complete response or disease worsening/progressing.</brief_summary>
	<brief_title>A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>This is a multicentre clinical study conducted in the United Kingdom. It is an open label study designed to investigate objective response rate (RR), the time to progression (TTP) and the duration of tumor response in patients with colorectal cancer when treated with CP-4055. The quantitative and qualitative toxicities of the treatment will also be assessed.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1. Patients with histologically or cytologically confirmed metastatic CRC who have failed a firstline chemotherapeutic regimen containing oxaliplatin and 5fluorouracil (5FU) with or without bevacizumab, with or without other Investigational Medicinal Products (IMPs) 2. Measurable disease according to Response Criteria In Solid Tumours (RECIST) 3. Performance Status 0 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status 4. Age 18 years or more 5. Life expectancy &gt; 3 months 6. Signed informed consent (IC) 7. Women of childbearing potential (i.e., women who are premenopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to CP4055 treatment. Nursing patients are excluded. 8. Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP4055 dose 9. Adequate haematological and biological functions 1. Known brain metastases 2. Radiotherapy to more than 30 % of bone marrow 3. Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study 4. Concomitant treatment with a nonpermitted medication: Alternative drugs High doses of vitamins 5. History of allergic reactions to araC or egg 6. Any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection) 7. Any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance 8. Pregnancy, breastfeeding or absence of adequate contraception for both male and female fertile patients 9. Known positive status for HIV and/or hepatitis B or C 10. Drug and/or alcohol abuse 11. Any reason why, in the investigator's opinion, the patient should not participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>CP-4055</keyword>
	<keyword>ELACYT(TM)</keyword>
	<keyword>Cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>CRC</keyword>
	<keyword>Second line therapy</keyword>
</DOC>